ClinicalTrials.gg

Bronchiolitis Obliterans Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 714 studies for Bronchiolitis Obliterans Syndrome across more than 10 countries. 128 are recruiting or about to start. 243 of them are mainly about Bronchiolitis Obliterans Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 783 studies for Bronchiolitis Obliterans Syndrome. How that becomes 714 here

This page counts the studies the registry files under Bronchiolitis Obliterans Syndrome, and those it files under no condition that list Bronchiolitis Obliterans Syndromethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 783Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −75Match it another way21 name it in the title and 54 by a synonym or other text the search reads.
  3. 708Counted here and found by its search1 of them list Bronchiolitis Obliterans Syndrome in their own words; the registry filed them under no condition.
  4. +6
    Counted here, but its search does not find them
  5. 714The count on this page

Status

Completed
390
Recruiting
100
Terminated
69
Status unknown
64
Active, not recruiting
39
Not yet recruiting
23

Phase

Phase 2
209
Phase 1
97
Phase 3
87
Phase 4
53
Early Phase 1
6

Where

United States
300
France
68
Canada
67
Germany
62
Spain
60
United Kingdom
59

Who develops what

Add Bronchiolitis Obliterans Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 8 companies, 5 with this as their studies’ main aim; 3 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Ausper Biopharma, Dompé Farmaceutici S.p.A and Incyte here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PrednisoneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06143891 · Sanofi · Phase 3 · live · background · “Prednisone” · registered Nov 2023
  • NCT03584516 · Incyte Corporation · Phase 3 · background · “Prednisone” · registered Jun 2018
  • NCT02959944 · AbbVie · Phase 3 · background · “Prednisone” · registered Oct 2016
Johnson & Johnson11% of its industry studies11 study
Adrenal Cortex HormonesRecent, limited
Evidence
  • NCT06585774 · Incyte Corporation · Phase 3 · live · background · “Corticosteroids” · registered Aug 2024
—11 study
TacrolimusRecent, limited
Evidence
  • NCT06615050 · Incyte Corporation · Phase 3 · live · background · “Tacrolimus (Tac)” · registered Sep 2024
Astellas Pharma Inc62% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 1 generic authorized11 study

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
DFL24498☆ Track1 live phase-3 study: NCT07395232Dompé Farmaceutici S.p.A
axatilimabApproved: US 2024☆ Track3 live phase-3 studies: NCT06585774, NCT06263478, NCT06821542Incyte Corporation
belumosudilApproved: US 2021 · EU 2026☆ Track2 live phase-3 studies: NCT07771439, NCT06143891Sanofi

The 3 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 6 Jan 2027 est.axatilimab · Incyte Corporation · Phase 2 main aimNCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD — primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs) · 32 enrolled
  • Mar 2027 est.DFL24498 · Dompé Farmaceutici S.p.A · Phase 3 main aimadded to dexamethasone phosphateNCT07395232 An Efficacy and Safety Study of DFL24498 in the Treatment of AKC — primary endpoint: Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS). · 153 enrolled
  • 30 Aug 2027 est.belumosudil · Sanofi · Phase 4 main aimNCT07135973 A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) — primary endpoint: Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) · 26 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Bronchiolitis Obliterans Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 7 open · JAK inhibitors 4 open · Alkylating agents 2 open · Local anesthetics 2 open · Corticosteroids 1 open

Coming up

45studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger. 25 (25%) take children under 18. 3 (3%) are for women only and 0 (0%) for men only; 12 (12%) take healthy volunteers.

Recruiting studies that take each age, of 100
AgeWomenMen
1015 (15%)14 (14%)
1891 (91%)88 (88%)
3093 (93%)90 (90%)
4095 (95%)92 (92%)
5093 (93%)90 (90%)
6589 (89%)87 (87%)
7562 (62%)60 (60%)
8548 (48%)46 (46%)

Across all 714 studies, recruiting or not: 37% stop at 75 or younger and 26% at 65; 18% take children; 2% are for women only and 1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Bronchiolitis Obliterans Syndrome studies take

Of 63 phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo18–65 · 22 studies——
Phase 1/264 mo37–87 · 24 studies——
Phase 235 mo23–58 · 63 studies—43 mo27–70 · 38 studies
Phase 334 mo19–62 · 30 studies——
Phase 422 mo17–79 · 16 studies——
Interventional, no phase22 mo11–54 · 122 studies—21 mo11–50 · 110 studies
Observational40 mo20–62 · 57 studies—42 mo15–75 · 49 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 714. Browse all 714 → or search them.